Candel Therapeutics, Inc. (CADL) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Candel Therapeutics, Inc.

CADL

NASDAQ

Unprofitable

229M

Biotechnology

Next Earning date - 13 May 2025

229M

Biotechnology

Next Earning date - 13 May 2025

4.84USD

-0.13 ( -2.62%)

Pre-market 4.88$

0.04 (0.72%)

Market Closed (as of Apr 29, 20:00 EDT)

Relative Strenght

Volume Buzz

-66%

Earning Acce

Dist 52w H.

67%

Overview Chart

Quote Panel

Updated April 30, 2025

1W -3.20 % 1M -14.34 % 3M -31.54 % 1Y -39.35 %

Key Metrics

Market Cap
228.62M
Shares Outstanding
47.24M
Share in Float
34.58M
Dividende
0

Earning Date
13 May 2025
Price Target
4.84
Average Volume
1.14M
Beta
-0.944

Range
3.785-14.6
Industry
Biotechnology
Website
https://www.candeltx.com
Sector
Healthcare

Quote Panel

Updated April 30, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

2.31x

P/B Ratio

0.2

Debt/Equity

0.0%

Net Margin

$-1.7

EPS

How CADL compares to sector?

P/E Ratio

Fundamentals

Relative Strength

CADL

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

CADL

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$4M

NaN%

2025-Revenue

$1.50

-242%

2025-EPS

$870K

94%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.30
vs -0.03

Q2.23

N/A

-0.33
vs -0.14

Q3.23

N/A

-0.29
vs -0.30

Q4.23

N/A

-0.38
vs -0.18

Q1.24

N/A

-0.28
vs -0.30

Q2.24

N/A

-0.74
vs -0.33

Q3.24

N/A

-0.33
vs -0.29

Q4.24

N/A

-0.40
vs -0.38

Q1.25

N/A

-0.37
vs -0.28

Q2.25

N/A

-0.40
vs -0.74

Sales Growth

YoY

Current

Estimates

Q3.22

31K vs 31K

Q4.22

31K vs 31K

Q1.23

-100%

NA vs 31K

Q2.23

-100%

NA vs 31K

Q3.23

-100%

NA vs 31K

Q4.23

+5629%

1.8M vs 31K

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 1.8M

Return on Equity

QoQ

Q1.23

-22%

-0.22
vs -0.11

Q2.23

-31%

-0.31
vs -0.22

Q3.23

-37%

-0.37
vs -0.31

Q4.23

-87%

-0.87
vs -0.37

Q1.24

-137%

-1.37
vs -0.87

Q2.24

+223%

2.23
vs -1.37

Q3.24

+70%

0.7
vs 2.23

Q4.24

-21%

-0.21
vs 0.7

Institutionnal Ownership

QoQ

Q1.23

20
vs 20

Q2.23

19
vs 20

-5%

Q3.23

19
vs 19

Q4.23

21
vs 19

11%

Q1.24

19
vs 21

-10%

Q2.24

49
vs 19

158%

Q3.24

56
vs 49

14%

Q4.24

78
vs 56

39%

Earnings Growth

Latest News

globenewswire.com

8 hours ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

proactiveinvestors.com

9 hours ago

Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409

proactiveinvestors.com

9 hours ago

Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI

globenewswire.com

16 hours ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

proactiveinvestors.com

16 hours ago

Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial

globenewswire.com

16 hours ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Company Description

4.84USD

N/A

0.00x

2.31x

0.2

0.0%

$-1.7

$4M

$1.50

$870K

Earnings Growth

Latest News

$4M

$1.50

$870K

Company Description

4.84USD

N/A

0.00x

2.31x

0.2

0.0%

$-1.7